Literature DB >> 1712861

Lack of enhancing effect of human anti-human immunodeficiency virus type 1 (HIV-1) antibody on HIV-1 infection of human blood monocytes and peritoneal macrophages.

P P Shadduck1, J B Weinberg, A F Haney, J A Bartlett, A J Langlois, D P Bolognesi, T J Matthews.   

Abstract

The influence of human anti-human immunodeficiency virus type 1 (HIV-1) antibody on HIV-1 infection of freshly isolated normal human peritoneal macrophages and blood monocytes was examined. Each of 14 HIV antibody-positive human serum samples was found to block the infection of four virus isolates (human T-cell lymphotropic virus type IIIBa-L [HTLV-IIIBa-L], HTLV-IIIB, D.U. 6587-7, and D.U. 7887-8) at serum dilutions ranging from 10(-1) to 10(-2). Three of these isolates (HTLV-IIIBa-L, D.U. 6587-7, and D.U. 7887-8) infected cultures of monocytes and macrophages rapidly and produced high levels of virus reverse transcriptase and p24 antigen. A fourth virus isolate (HTLV-IIIB) infected the monocytes and macrophages more slowly and produced low levels of viral protein. More dilute HIV antibody-positive sera had no significant effect on the overall level or rate of virus infection or expression. Complement did not appear to influence the course of infection by any combination of antisera or virus examined. Successful HIV-1 infection of the peritoneal macrophages and blood monocytes under the conditions tested showed strict dependence on CD4 since a recombinant CD4 polypeptide and an anti-CD4 monoclonal antibody effectively blocked the process.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1712861      PMCID: PMC248869     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  50 in total

1.  Persistent HIV antigenaemia and decline of HIV core antibodies associated with transition to AIDS.

Authors:  J M Lange; D A Paul; H G Huisman; F de Wolf; H van den Berg; R A Coutinho; S A Danner; J van der Noordaa; J Goudsmit
Journal:  Br Med J (Clin Res Ed)       Date:  1986-12-06

2.  Quantitative immunocytofluorographic analysis of CD4 surface antigen expression and HIV infection of human peripheral blood monocyte/macrophages.

Authors:  S Crowe; J Mills; M S McGrath
Journal:  AIDS Res Hum Retroviruses       Date:  1987       Impact factor: 2.205

3.  In vitro infection of human monocytes with human T lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV).

Authors:  J K Nicholson; G D Cross; C S Callaway; J S McDougal
Journal:  J Immunol       Date:  1986-07-01       Impact factor: 5.422

4.  Complement-mediated, antibody-dependent enhancement of HIV-1 infection in vitro is characterized by increased protein and RNA syntheses and infectious virus release.

Authors:  W E Robinson; D C Montefiori; D H Gillespie; W M Mitchell
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1989

Review 5.  Membrane complement receptors specific for bound fragments of C3.

Authors:  G D Ross; M E Medof
Journal:  Adv Immunol       Date:  1985       Impact factor: 3.543

6.  The Walter Reed staging classification for HTLV-III/LAV infection.

Authors:  R R Redfield; D C Wright; E C Tramont
Journal:  N Engl J Med       Date:  1986-01-09       Impact factor: 91.245

Review 7.  Structure and function of human and murine receptors for IgG.

Authors:  J C Unkeless; E Scigliano; V H Freedman
Journal:  Annu Rev Immunol       Date:  1988       Impact factor: 28.527

8.  HTLV-III-neutralizing antibodies in patients with AIDS and AIDS-related complex.

Authors:  M Robert-Guroff; M Brown; R C Gallo
Journal:  Nature       Date:  1985 Jul 4-10       Impact factor: 49.962

9.  Neutralization of human T-lymphotropic virus type III by sera of AIDS and AIDS-risk patients.

Authors:  R A Weiss; P R Clapham; R Cheingsong-Popov; A G Dalgleish; C A Carne; I V Weller; R S Tedder
Journal:  Nature       Date:  1985 Jul 4-10       Impact factor: 49.962

10.  A human immunodeficiency virus type 1 (HIV-1) infection-enhancing factor in seropositive sera.

Authors:  W E Robinson; D C Montefiori; W M Mitchell
Journal:  Biochem Biophys Res Commun       Date:  1987-12-16       Impact factor: 3.575

View more
  8 in total

Review 1.  Role of complement and Fc receptors in the pathogenesis of HIV-1 infection.

Authors:  D C Montefiori
Journal:  Springer Semin Immunopathol       Date:  1997

2.  HIV-1 infection of in vitro cultured human monocytes: early events and influence of anti HIV-1 antibodies.

Authors:  M Arendrup; S Olofsson; J O Nielsen; J E Hansen
Journal:  Arch Virol       Date:  1994       Impact factor: 2.574

Review 3.  Pathogenesis of human immunodeficiency virus infection.

Authors:  J A Levy
Journal:  Microbiol Rev       Date:  1993-03

4.  Human peritoneal macrophages from ascitic fluid can be infected by a broad range of HIV-1 isolates.

Authors:  Theresa L Chang; Arielle Klepper; Jian Ding; John Garber; Aprille Rapista; Arevik Mosoian; Wolfgang Hubner; Julio Gutierrez; Jose Walewski; Jeffrey Abergel; Thomas Schiano; Andrea Branch
Journal:  J Acquir Immune Defic Syndr       Date:  2010-03       Impact factor: 3.731

5.  Fcgamma receptor-mediated suppression of human immunodeficiency virus type 1 replication in primary human macrophages.

Authors:  Danielle Perez-Bercoff; Annie David; Hugues Sudry; Françoise Barré-Sinoussi; Gianfranco Pancino
Journal:  J Virol       Date:  2003-04       Impact factor: 5.103

6.  Cellular CD44S as a determinant of human immunodeficiency virus type 1 infection and cellular tropism.

Authors:  C S Dukes; Y Yu; E D Rivadeneira; D L Sauls; H X Liao; B F Haynes; J B Weinberg
Journal:  J Virol       Date:  1995-07       Impact factor: 5.103

7.  Productive human immunodeficiency virus type 1 (HIV-1) infection of nonproliferating human monocytes.

Authors:  J B Weinberg; T J Matthews; B R Cullen; M H Malim
Journal:  J Exp Med       Date:  1991-12-01       Impact factor: 14.307

8.  Immune suppression by neutrophils in HIV-1 infection: role of PD-L1/PD-1 pathway.

Authors:  Nathan L Bowers; E Scott Helton; Richard P H Huijbregts; Paul A Goepfert; Sonya L Heath; Zdenek Hel
Journal:  PLoS Pathog       Date:  2014-03-13       Impact factor: 6.823

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.